Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options
has been studied and deployed. Healthcare providers have multiple treatment approaches …

Over four years have passed since the beginning of the COVID-19 pandemic. The scientific
response has been rapid and effective, with many therapeutic monoclonal antibodies and …

Coronaviruses (CoVs) encode nonstructural proteins 1–16 (nsps 1–16) which form replicase
complexes that mediate viral RNA synthesis. Remdesivir (RDV) is an adenosine nucleoside …

The cap-snatching mechanism mediated by cap-dependent endonuclease, which is
common among the negative-stranded, segmented RNA viruses in Orthomyxoviridae …

Numerous SARS-CoV-2 variant strains with altered characteristics have emerged since the
onset of the COVID-19 pandemic. Remdesivir (RDV), a ribonucleotide analogue inhibitor of …

A primary reason for the ongoing spread of coronavirus disease 2019 (COVID-19) is the
continuous acquisition of mutations by the severe acute respiratory syndrome coronavirus 2 …

Although the coronavirus disease 2019 (COVID-19) pandemic is coming to an end, it still
poses a threat to the immunocompromised and others with underlying diseases. Especially …

Abstract SARS-CoV-2, the causative agent of COVID-19, has had a devastating impact,
resulting in over 7 million deaths worldwide. Like most viruses, SARS-CoV-2 has continued …